Jack A Roth

List of Publications by Year
in descending order

195 papers	11,649 citations	47 h-index 47006	101 g-index 31849
246 all docs	246 docs citations	246 times ranked	15016 citing authors

#	Article	IF	Citations
1	Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008, 455, 1069-1075.	27.8	2,694
2	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncology, The, 2015, 16, 630-637.	10.7	1,220
3	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	16.8	422
4	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
5	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	7.0	292
6	Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2012, 7, 825-832.	1.1	280
7	Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer, 1992, 69, 662-668.	4.1	246
8	Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a â€œNo Fly Zoneâ€• International Journal of Radiation Oncology Biology Physics, 2014, 88, 1120-1128.	0.8	225
9	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	13.2	218
10	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncology, The, 2021, 22, 1448-1457.	10.7	154
11	Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. Annals of Thoracic Surgery, 2018, 106, 272-279.	1.3	153
12	Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans. PLoS ONE, 2012, 7, e34833.	2.5	149
13	Overexpression of the wild-type p53 gene inhibits NF-ÎºB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene, 2000, 19, 726-736.	5.9	134
14	Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene, 1997, 14, 379-384.	5.9	131
15	Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene, 2001, 20, 5225-5231.	5.9	128
16	7â€year followâ€up after stereotactic ablative radiotherapy for patients with stage I nonâ€“small cell lung cancer: Results of a phase 2 clinical trial. Cancer, 2017, 123, 3031-3039.	4.1	125
17	A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer, 2001, 92, 279-286.	4.1	119
18	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118

#	Article	IF	Citations
19	Adenovirus p53 gene therapy. Expert Opinion on Biological Therapy, 2006, 6, 55-61.	3.1	117
20	Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Therapy, 2004, 11, 733-739.	4.6	116
21	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget, 2016, 7, 3548-3558.	1.8	114
22	Thoracoscopic lobectomy is associated with improved short-term and equivalent oncological outcomes compared with open lobectomy for clinical Stage I non-small-cell lung cancer: a propensity-matched analysis of 963 cases. European Journal of Cardio-thoracic Surgery, 2014, 46, 607-613.	1.4	112
23	Adenovirus-mediated wild-typep53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Annals of Surgical Oncology, 1998, 5, 681-688.	1.5	111
24	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	1.1	109
25	Thep53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. Journal of Cancer Research and Clinical Oncology, 1996, 122, 360-365.	2.5	108
26	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107
27	Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Chest, 2009, 136, 701-709.	0.8	105
28	An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunology Research, 2019, 7, 1267-1279.	3.4	92
29	Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. , 1996, 17, 217-223.		89
30	Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Nonâ€“Small Cell Lung Cancer Cells. Journal of the National Cancer Institute, 2014, 106, .	6.3	88
31	p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene, 1997, 15, 1903-1909.	5.9	84
32	Overexpression of candidate tumor suppressor gene FUS1 isolated from the 3p21.3 homozygous deletion region leads to G1 arrest and growth inhibition of lung cancer cells. Oncogene, 2001, 20, 6258-6262.	5.9	82
33	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Letters, 2015, 357, 179-185.	7.2	81
34	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	7.0	80
35	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	1.1	79
36	Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature, 2021, 590, 504-508.	27.8	79

#	Article	IF	Citations
37	Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene, 1999, 18, 2189-2199.	5.9	72
38	Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene, 1998, 16, 1-8.	5.9	70
39	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clinical Lung Cancer, 2020, 21, 341-348.	2.6	70
40	Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene, 2000, 19, 4432-4436.	5.9	69
41	Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53). Cancer Gene Therapy, 2000, 7, 530-536.	4.6	63
42	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
43	Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene, 1998, 17, 241-246.	5.9	61
44	Drug resistance in lung cancer. Lung Cancer: Targets and Therapy, 2010, 1, 23-36.	2.7	59
45	Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. Annals of Thoracic Surgery, 2019, 108, 370-376.	1.3	58
46	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	12.8	58
47	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research, 2019, 79, 125-132.	0.9	56
48	Diaphragmatic Hernia After Esophagectomy in 440 Patients With Long-Term Follow-Up. Annals of Thoracic Surgery, 2013, 96, 1138-1145.	1.3	55
49	A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer. Carcinogenesis, 2019, 40, 643-650.	2.8	52
50	Modification of Tumor Suppressor Gene Expression and Induction of Apoptosis in Non-Small Cell Lung Cancer (NSCLC) with an Adenovirus Vector Expressing Wildtype p53 and Cisplatin. University of Texas M.D. Anderson Cancer Center, Houston, Texas. Human Gene Therapy, 1996, 7, 1013-1030.	2.7	50
51	Novel combination therapy for human colon cancer with adenovirus-mediated wild-typep53 gene transfer and DNA-damaging chemotherapeutic agent. , 1997, 73, 367-370.		50
52	Adenovirus-mediated p16INK4a gene expression radiosensitizes non-small cell lung cancer cells in a p53-dependent manner. Oncogene, 2000, 19, 5359-5366.	5.9	47
53	Efficacy of pulmonary metastasectomy for recurrent soft tissue sarcoma. Journal of Surgical Oncology, 1991, 47, 1-4.	1.7	46
54	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Nonâ€“small-cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2019, 20, 43-47.	2.6	45

#	Article	IF	Citations
55	STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research, 2021, 27, 1720-1733.	7.0	44
56	Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. Cancer, 1995, 75, 451-456.	4.1	43
57	Overexpression of the p21 sdi1 gene induces senescence-like state in human cancer cells: implication for senescence-directed molecular therapy for cancer. Cell Death and Differentiation, 1999, 6, 765-772.	11.2	42
58	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 601-609.	1.1	40
59	Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Therapy, 2000, 7, 537-544.	4.6	36
60	The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. Annals of Thoracic Surgery, 2016, 102, 1653-1659.	1.3	34
61	Glycemic Index, Glycemic Load, and Lung Cancer Risk in Non-Hispanic Whites. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 532-539.	2.5	33
62	Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1648-1655.	0.8	33
63	Modification of Mutant K-ras Gene Expression in Non-Small Cell Lung Cancer (NSCLC). University of Texas M.D. Anderson Cancer Center, Houston, Texas. Human Gene Therapy, 1996, 7, 875-889.	2.7	31
64	Serum MicroRNAâ€150 Predicts Prognosis for Earlyâ€Stage Nonâ€Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clinical Pharmacology and Therapeutics, 2018, 103, 1061-1073.	4.7	31
65	Tumor characteristics associated with engraftment of patientâ€derived nonâ€“small cell lung cancer xenografts in immunocompromised mice. Cancer, 2019, 125, 3738-3748.	4.1	31
66	Prognostic indicators in patients with pulmonary metastases. Journal of Surgical Oncology, 1990, 6, 291-296.	1.4	30
67	TUSC2 Immunogene Therapy Synergizes with Antiâ€“PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunology Research, 2018, 6, 163-177.	3.4	30
68	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1327-1337.	0.8	29
69	Retroviral-mediated transduction ofp53 gene increases TGF-Î² expression in a human glioblastoma cell line. International Journal of Cancer, 1994, 56, 834-839.	5.1	27
70	Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis. Oncogene, 1998, 17, 901-906.	5.9	27
71	Gene replacement therapy for nonâ€“small cell lung cancer: a review. Hematology/Oncology Clinics of North America, 2004, 18, 215-229.	2.2	27
72	Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS ONE, 2015, 10, e0123967.	2.5	27

#	Article	IF	Citations
73	MicroRNA-mediated target mRNA cleavage and 3â€²-uridylation in human cells. Scientific Reports, 2016, 6, 30242.	3.3	26
74	Loss of Î±1Î²1 and reduced expression of other Î²1 integrins and cam in lung adenocarcinoma compared with pneumocytes. Journal of Surgical Oncology, 1994, 56, 198-208.	1.7	25
75	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research, 2017, 5, 319-329.	3.4	25
76	The Molecular Genetics of Lung Cancer. , 0, , 61-83.		24
77	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. European Journal of Cardio-thoracic Surgery, 2021, 59, 100-108.	1.4	23
78	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	12.8	23
79	TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Scientific Reports, 2016, 6, 35741.	3.3	22
80	Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Medicine, 2018, 7, 2405-2414.	2.8	22
81	Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. Annals of Surgery, 2021, 274, 1099-1106.	4.2	22
82	MicroRNA-124 Suppresses Tumor Cell Proliferation and Invasion by Targeting CD164 Signaling Pathway in Non-Small Cell Lung Cancer. Journal of Gene Therapy, 2016, 2, .	1.0	22
83	Gene Therapy for Lung Cancer. Critical Reviews in Oncogenesis, 2016, 21, 115-124.	0.4	21
84	Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 911-919.e6.	0.8	21
85	Predictors of survival after resection of primary sarcomas of the chest wallâ€”A large, singleâ€institution series. Journal of Surgical Oncology, 2018, 118, 518-524.	1.7	20
86	Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. Journal of Surgical Oncology, 2019, 120, 729-735.	1.7	20
87	Analysis of phosphorylated isoforms of the p53 tumor suppressor protein in human lung carcinoma cells undergoing apoptosis. Electrophoresis, 1996, 17, 1772-1775.	2.4	19
88	Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients. Carcinogenesis, 2014, 35, 1284-1291.	2.8	19
89	Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. Annals of Thoracic Surgery, 2016, 102, 276-281.	1.3	19
90	Predictors of trimodality therapy and trends in therapy for malignant pleural mesotheliomaâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 960-966.	1.4	19

#	Article	IF	Citations
91	Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 1671-1677.	1.3	19
92	TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget, 2017, 8, 107621-107629.	1.8	19
93	The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner. PLoS ONE, 2013, 8, e77067.	2.5	18
94	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Annals of Thoracic Surgery, 2016, 101, 1075-1081.	1.3	18
95	Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.. Scientific Reports, 2016, 6, 26760.	3.3	18
96	Inflammation-Related Genetic Variations and Survival in Patients With Advanced Nonâ€“Small Cell Lung Cancer Receiving First-Line Chemotherapy. Clinical Pharmacology and Therapeutics, 2014, 96, 360-369.	4.7	16
97	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene, 2020, 39, 801-813.	5.9	16
98	Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Annals of Thoracic Surgery, 2022, 113, 200-208.	1.3	16
99	Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Lung Cancer, 2017, 114, 70-78.	2.0	15
100	Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing. Annals of Thoracic Surgery, 2019, 107, 936-940.	1.3	15
101	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network Open, 2022, 5, e2215589.	5.9	15
102	Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. OncoImmunology, 2018, 7, e1376156.	4.6	14
103	Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Annals of Thoracic Surgery, 2019, 108, 845-851.	1.3	14
104	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 1404-1412.e2.	0.8	14
105	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest, 2021, 159, 1256-1264.	0.8	14
106	Gene therapy in lung cancer. Current Oncology Reports, 2000, 2, 64-70.	4.0	13
107	Tumor Suppressor Gene Therapy. , 2003, 223, 577-598.		13
108	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clinical Cancer Research, 2019, 25, 150-157.	7.0	13

#	Article	IF	Citations
109	Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. Annals of Thoracic Surgery, 2018, 106, 235-241.	1.3	12
110	Occult stage IIIA-N2 patients have excellent overall survival with initial surgery. Journal of Thoracic Disease, 2018, 10, 6670-6676.	1.4	12
111	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. Journal of Translational Medicine, 2018, 16, 328.	4.4	12
112	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40.	2.0	12
113	Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. Annals of Thoracic Surgery, 2022, 113, 975-983.	1.3	12
114	Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients. Scientific Reports, 2015, 5, 12068.	3.3	11
115	Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cellâ€free DNA by nextâ€generation sequencing. Cancer, 2018, 124, 1061-1069.	4.1	11
116	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
117	Surgery versus SABR for resectable non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e374-e375.	10.7	10
118	Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy. Carcinogenesis, 2017, 38, 419-424.	2.8	10
119	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. British Journal of Cancer, 2018, 118, 331-337.	6.4	10
120	Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. Targeted Oncology, 2018, 13, 99-106.	3.6	10
121	Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Nonâ€“Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clinical Lung Cancer, 2020, 21, e294-e301.	2.6	10
122	Time trends and predictors of survival in surgically resected earlyâ€stage nonâ€“small cell lung cancer patients. Journal of Surgical Oncology, 2020, 122, 495-505.	1.7	10
123	Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. Oncotarget, 2015, 6, 345-354.	1.8	10
124	Limitations of 18F-2-Deoxy-d-Glucose Positron Emission Tomography in N1 Detection in Patients With Pathologic Stage II-N1 and Implications for Management. Annals of Thoracic Surgery, 2015, 99, 414-420.	1.3	9
125	Genetic associations of T cell cancer immune response-related genes with T cell phenotypes and clinical outcomes of early-stage lung cancer. , 2020, 8, e000336.		9
126	Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. Annals of Thoracic Surgery, 2021, 112, 423-429.	1.3	9

#	Article	IF	Citations
127	Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9017-9017.	1.6	9
128	Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics. Oncotarget, 2017, 8, 48222-48239.	1.8	9
129	Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380. Bioorganic and Medicinal Chemistry, 2014, 22, 5234-5240.	3.0	8
130	Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis. Biochemistry and Biophysics Reports, 2016, 6, 16-23.	1.3	8
131	Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction?. Annals of Thoracic Surgery, 2017, 103, 1710-1714.	1.3	8
132	Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. Annals of Thoracic Surgery, 2020, 109, 404-411.	1.3	8
133	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Annals of Thoracic Surgery, 2020, 110, 1131-1138.	1.3	8
134	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Annals of Thoracic Surgery, 2022, 114, 2032-2040.	1.3	8
135	Influence of Age on Choice of Therapy and Surgical Outcomes in Patients with Nonsmall Cell Lung Cancer. American Surgeon, 2009, 75, 598-604.	0.8	7
136	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Nonâ€“Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0150467.	2.5	7
137	Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. Annals of Thoracic Surgery, 2017, 104, 1821-1828.	1.3	7
138	Preoperative Maximum Standardized Uptake Value Associated with Recurrence Risk In Early Lung Cancer. Annals of Thoracic Surgery, 2021, , .	1.3	7
139	RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget, 2015, 6, 11114-11124.	1.8	7
140	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	3.1	7
141	Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. Annals of Thoracic Surgery, 2018, 106, 1499-1503.	1.3	6
142	Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. Journal of Thoracic Disease, 2019, 11, 3391-3398.	1.4	6
143	From clinical specimens to human cancer preclinical modelsâ€”a journey the NCIâ€cell line databaseâ€”25 years later. Journal of Cellular Biochemistry, 2020, 121, 3986-3999.	2.6	6
144	Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 337-343.	0.6	6

#	Article	IF	Citations
145	Esophageal cancer: Does preoperative chemotherapy make a difference?. Journal of Surgical Oncology, 1992, 50, 67-69.	1.7	5
146	Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2635-2645.e15.	0.8	5
147	Hospital readmissions after pulmonary resection: post-discharge nursing telephone assessment identifies high risk patients. Journal of Thoracic Disease, 2020, 12, 184-190.	1.4	5
148	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Annals of Thoracic Surgery, 2021, 111, 1133-1140.	1.3	5
149	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. American Journal of Cancer Research, 2020, 10, 4464-4475.	1.4	5
150	TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Communications Biology, 2022, 5, 167.	4.4	5
151	Somatostatin Receptor Type 2â€“Based Reporter Expression after Plasmid-Based in Vivo Gene Delivery to Nonâ€“Small Cell Lung Cancer. Molecular Imaging, 2013, 12, 7290.2013.00060.	1.4	4
152	Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. Journal of Thoracic Disease, 2020, 12, 329-337.	1.4	4
153	Gene Therapy in Thoracic Oncology. Annals of Thoracic Surgery, 2008, 85, 1837-1838.	1.3	3
154	Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2020, 15, 57-65.	0.9	3
155	Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. Journal of Surgical Oncology, 2020, 122, 515-522.	1.7	3
156	Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy. Journal of Gastrointestinal Surgery, 2021, 25, 2185-2191.	1.7	3
157	Novel combination therapy for human colon cancer with adenovirusâ€mediated wildâ€type p53 gene transfer and DNAâ€damaging chemotherapeutic agent. International Journal of Cancer, 1997, 73, 367-370.	5.1	3
158	Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. Oncotarget, 2017, 8, 102150-102160.	1.8	3
159	Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Scientific Reports, 2022, 12, 1248.	3.3	3
160	Extended Resections for Lung Cancer. , 0, , 194-220.		3
161	Molecular determinants of cell death induction following adenovirus-mediated gene transfer of wild-type p53 in prostate cancer cells. International Journal of Cancer, 2001, 91, 159-166.	5.1	2
162	Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer â€“ Authors' reply. Lancet Oncology, The, 2016, 17, e42-e43.	10.7	2

#	Article	IF	Citations
163	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer, 2020, 146, 303-309.	2.0	2
164	Pulmonary resection for tissue harvest in adoptive tumorâ€infiltrating lymphocyte therapy: Safety and feasibility. Journal of Surgical Oncology, 2021, 124, 699-703.	1.7	2
165	Detection of Preneoplastic Lesions. , 0, , 99-110.		2
166	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer, 2022, 164, 69-75.	2.0	2
167	High mutational concordance between primary colorectal tumors and associated pulmonary metastases. Journal of Surgical Oncology, 2020, 121, 984-989.	1.7	1
168	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.. Journal of Clinical Oncology, 2021, 39, 4067-4067.	1.6	1
169	Lung Cancer Susceptibility and Risk Assessment Models. , 0, , 33-60.		1
170	Molecular Biology of Preneoplastic Lesions of the Lung. , 0, , 84-98.		1
171	Glutathione reductase () gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. American Journal of Cancer Research, 2019, 9, 1201-1211.	1.4	1
172	Stereotactic Body Radiation Therapy for Lung Cancer. , 0, , 256-270.		1
173	The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. Journal of Surgical Research, 2022, 277, 125-130.	1.6	1
174	Comparison of outcomes between muscle-sparing thoracotomy and video-assisted thoracic surgery in patients with cT1 N0 M0 lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1307.	0.8	0
175	Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. Annals of Thoracic Surgery, 2021, 111, 1111-1117.	1.3	0
176	Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. Annals of Thoracic Surgery, 2021, , .	1.3	0
177	Treatment of esophageal cancer: does surgery make the cut?. Gastrointestinal Cancer Research: GCR, 2007, 1, 207-8.	0.7	0
178	SABR for operable stage I non-small-cell lung cancer: comparison to surgery â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e537-e538.	10.7	0
179	Molecular Profiling for Early Detection and Prediction of Response in Lung Cancer. , 0, , 153-168.		0
180	The Role for Mediastinoscopy in the Staging of Nonsmall Cell Lung Cancer. , 0, , 169-179.		0

#	Article	IF	Citations
181	Minimally Invasive Surgery for Lung Cancer. , 0, , 180-193.		0
182	Adjuvant Chemotherapy Following Surgery for Lung Cancer. , 0, , 221-232.		0
183	Image-Guided Radiation Therapy. , 0, , 247-255.		0
184	Proton Therapy. , 0, , 271-282.		0
185	Combinations of Radiation Therapy and Chemotherapy for Nonsmall Cell Lung Carcinoma. , 0, , 283-314.		0
186	New Chemotherapeutic Agents in Lung Cancer. , 0, , 315-333.		0
187	Immunologic Approaches to Lung Cancer Therapy. , 0, , 334-351.		0
188	Epidermal Growth Factor Receptor Inhibitors. , 0, , 352-368.		0
189	Proteasome Inhibition in Nonsmall Cell Lung Cancer Therapy. , 0, , 400-410.		0
190	Screening for Early Detection. , 0, , 421-440.		0
191	Natural Agents for Chemoprevention of Lung Cancer. , 0, , 441-455.		0
192	The Pathology and Pathogenesis of Peripheral Lung Adenocarcinoma Including Bronchioloalveolar Carcinoma. , 0, , 121-143.		0
193	Treatment of Bronchioloalveolar Carcinoma. , 0, , 144-152.		0
194	Tumour-Suppressor Gene Therapy. , 0, , 229-239.		0
195	Molecular parameters impacting the success rate of a lung cancer PDX model.. Journal of Clinical Oncology, 2022, 40, e20592-e20592.	1.6	0